Pacific Biosciences Of California, Inc. (PACB) Files Form 4 Insider Selling : James Michael Phillips Sells 20,000 Shares

Pacific Biosciences Of California, Inc. (PACB): James Michael Phillips , SVP, Research & Development of Pacific Biosciences Of California, Inc. sold 20,000 shares on Apr 25, 2016. The Insider selling transaction was reported by the company on Apr 26, 2016 to the Securities and Exchange Commission. The shares were sold at $10.29 per share for a total value of $205,720.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Aug 11, 2015, James Michael Phillips (SVP, Research & Development) sold 16,689 shares at $4.61 per share price.On Mar 2, 2015, Kevin P Corcoran (SVP, Market Development) purchased 2,816 shares at $4.91 per share price.Also, On Mar 2, 2015, Brian B Dow (VP and PAO) purchased 2,503 shares at $4.91 per share price.

Pacific Biosciences of California: On Friday, Apr 22, 2016 heightened volatility was witnessed in Pacific Biosciences of California which led to swings in the share price. The shares opened for trading at $9.6 and hit $10.75 on the upside , eventually ending the session at $10.72, with a gain of 19.24% or 1.73 points. The heightened volatility saw the trading volume jump to 55,55,166 shares. The 52-week high of the share price is $14 and the company has a market cap of $919 M . The 52-week low of the share price is at $3.58.

Pacific Biosciences of California Money Flow Index Chart

Company has been under the radar of several Street Analysts.Pacific Biosciences of California is Initiated by First Analysis Sec to Overweight and the brokerage firm has set the Price Target at $11. The Rating was issued on Apr 15, 2016.Pacific Biosciences of California is Downgraded by Piper Jaffray to Neutral. Earlier the firm had a rating of Overweight on the company shares. The Rating was issued on Feb 4, 2016.

Pacific Biosciences of California Inc. designs develops and manufactures the PacBio RS II Sequencing System to help scientists resolve genetically complex problems. Based on the Company’s Single Molecule Real-Time (SMRT) technology its products enable de novo genome assembly to finish genomes in order to more fully identify annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes characterize alternatively spliced isoforms and find genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA (deoxyribonucleic acid) base modification identification to help characterize epigenetic regulation and DNA damage. SMRT enables single molecule real-time detection of biological processes. Based on its SMRT technology the Company introduced the PacBio RS II System to address many of the limitations.

Leave a Reply

Pacific Biosciences of California - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pacific Biosciences of California. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.